داكلاتاسفير ثنائي هيدروكلوريد
| Kind | API |
|---|---|
| Class | Antiviral — HCV NS5A inhibitor |
| Synonyms | DCV, Daclatasvir 2HCl, BMS-790052, Daklinza |
| Common uses / forms | Oral tablets for chronic hepatitis C, given together with sofosbuvir |
| Properties | BCS Class II (pH-dependent solubility, high permeability); near-symmetric bis-imidazole molecule; dihydrochloride salt improves dissolution |
| Compendia | IP |
| Sourcing origins | India, China |
| Dominant inbound route | Hormuz |
| Indicative price band | $$$ ($100–1000 / kg) |
| Indicative lead time | medium (50–80 days) |
| Notes | Compendia pruned: USP removed — US brand (Daklinza) discontinued 2019 and a finalized USP-NF daclatasvir monograph is not confidently confirmed; kept IP only (India/Egypt is the dominant generic base). Salt/polymorph control key; usually co-prescribed with sofosbuvir |
Open the interactive Data Bank (363 substances) · the full table · Supply Resilience Studio
Share: LinkedIn · X · WhatsApp · Telegram · Email
Cite as: AUPAM Experts' Office, Daclatasvir dihydrochloride — sourcing profile (API) — AUPAM Data Bank, retrieved 2026-08-31, https://aupameo.org/datasets/databank/a-daclatasvir-dihydrochloride.html